Cargando…
MON-196 A Single-Center Experience of Patients with Metastatic Pheochromocytoma/Paraganglioma Treated with (177)Lu-DOTATATE
The prevalence of metastatic pheochromocytoma/paraganglioma (PPGL) is reported to be 3% to 36% of all the cases. The five-year overall survival rate of such patients ranges from 40 to 77%. The management of metastatic PPGL is challenging taking into account the fact that the optimal strategies for c...
Autores principales: | Roslyakova, Anna, Beltsevich, Dmitry, Plotkin, Michail, Rumyantsev, Pavel, Ladygina, Daria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209615/ http://dx.doi.org/10.1210/jendso/bvaa046.1812 |
Ejemplares similares
-
MON-214 Biochemical Abnormalities in Endocrine Function Associated with Lutetium 177-DOTATATE Therapy in Metastatic Pheochromocytoma and Paraganglioma
por: Gubbi, Sriram, et al.
Publicado: (2020) -
(177)Lu-DOTATATE therapy in metastatic/inoperable pheochromocytoma-paraganglioma
por: Kumar Jaiswal, Sanjeet, et al.
Publicado: (2020) -
SHDB mutant functional metastatic paraganglioma: The efficacy of Lutetium-177 DOTATE
por: Erturk, Banu, et al.
Publicado: (2023) -
Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with (177)Lu-DOTATATE
por: Vyakaranam, Achyut Ram, et al.
Publicado: (2019) -
MON-199 Targeting Pheochromocytoma/Paraganglioma with Polyamine Inhibitors
por: Ghayee, Hans Kumar, et al.
Publicado: (2020)